Correction to Treatments for Macular Degeneration Article on June 8 -- Journal Report
10 Junho 2020 - 3:50PM
Dow Jones News
In a Phase 1-2 trial of Regenxbio's RGX-314 gene therapy for
age-related macular degeneration, levels of an antibody produced by
the treatment, which blocks a protein that causes AMD, hadn't
diminished in one patient group two years after injection of the
drug, and patients at the highest dose cohort experienced an
improvement in their vision six months after injection. "New
Treatments for Macular Degeneration Are on the Way," at 7:19 p.m.
ET on June 8, incorrectly gave the time frame over which the
antibody levels hadn't fallen as 18 months, and didn't include the
time frame for improved vision in the highest dose cohort. Also,
Regenxbio now plans to begin Phase 3 trials of RGX-314 this year.
The article said the company planned to start Phase 3 trials by
early next year.
(END) Dow Jones Newswires
June 10, 2020 14:35 ET (18:35 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.